Aarti Drugs Ltd. share price target

We maintain our recommendation of BUY on the stock.

We maintain our BUY rating on the stock.

We have BUY on the stock

We recommend a BUY rating on the stock with a target price of Rs 536/share, implying an upside of 10% from CMP

Company Outlook & Guidance: In the API sector, a positive shift in the export landscape is anticipated in the near future, supported by interest rate reductions, low stock levels, and an upswing in demand. We have BUY on stock

It is expected that API's realisations could be on lower side along elevated key solvents as the industry is facing oversupply.

We expect demand for API to continue in the upcoming quarters with easing supply chain bottlenecks. We believe that Aarti Drugs, being a leader in the domestic industry, is well-placed to capitalize on prevalent as well as future growth opportunities.

We believe that Aarti Drugs, being a leader in the domestic industry, is well-placed to capitalize on prevalent as well as future growth opportunities. We have BUY rating on stock.

Multiple capex nearing completion

Company Outlook & Guidance: Most of the API players reported an increase in volume uptick backed by improved demand and stable realisations. We expect demand for API to continue in the upcoming quarters with the ease of supply chain bottlenecks. Aarti Drugs, being a leader in the domestic industry,

We recommend a BUY rating on the stock

Aarti Drugs could be benefitted in upcoming quarters, we upgrade to BUY on Aarti Drugs with Target Price of Rs 545

We believe the company's profitability might be hit due to the above factors, prompting us to recommend a HOLD rating on the stock with TP Rs 450/share.

Furthermore, the raw material prices for API manufacturing have shown softness which will support the company's growth in the upcoming quarters. We recommend HOLD with the target price of Rs 540/share.

We believe this trend will continue for the upcoming quarters and therefore recommend HOLD rating 0n the stock with a Target Price of Rs 645/share.

We expect revenue and PAT CAGR of 13.3% and 12.3% respectively over the period FY21-FY23E and recommend BUY with TP of Rs 760.

We expect revenue and PAT CAGR of 15.9% and 15.3% respectively over the period FY21-FY23E and recommend a Buy with TP of INR 840.

We expect revenue and PAT CAGR of 18.2% and 37.6% respectively over the period FY20-FY23E and recommend Buy with TP of INR 812.

ARTD is engaged in the manufacturing of Active Pharmaceutical Ingredients (APIs) Pharma Intermediates and Specialty Chemicals. Products under APIs includes Ciprofloxacin, Hydrochloride, Metronidazole, Metformin HCL, etc. whereas Specialty Chemicals includes Benzene Sulphonyl Chloride, Methyl Nicotin

We expect revenue and PAT CAGR of 18.2% and 37.6% respectively over the period FY20-FY23E and recommend "Buy" with TP of INR 812.